TNFRSF4 and tuberculosis: We previously reported that combinatory immunoprofiling using FC detection of AIM CD25+ and CD134+ in T-cells following ex vivo antigen challenge in PBMCs can differentiate treated and untreated latent TB infection and might identify patients at risk for future TB reactivation [12].